G17DT
G17DT Uses, Dosage, Side Effects, Food Interaction and all others data.
G17DT is a vaccine that neutralises gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.
G17DT is a vaccine which neutralizes the gastrin 17 (G17) hormone and glycine-extended gastrin 17. G17 is a growth factor for pancreatic, stomach and colorectal cancers, and a potent stimulator of gastric acid secretion. G17DT consists of a protein carrier (Diptheria Toxoid) and a synthetic peptide which is similar to a portion of the gastrin 17 hormone. These are contained in a 'slow-release' liquid suspension vehicle for intramuscular administration. G17DT is administered by injection, the initial schedule for injection is unclear at present but boosterdoses are given at approximately six monthly intervals.
Trade Name | G17DT |
Generic | G17DT |
G17DT Other Names | Antigastrin 17, Gastrin 17 immunogen, Gastrin 17 vaccine |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Intended for the treatment of various forms of cancer.
How G17DT works
When administered, G17DT induces an immune response producing antibodies which bind with the peptide and also cross-react and neutralise gastrin 17 thus inhibiting the growth of gastrointestinal cancers and metastasis. In addition the product neutralizes glycine-extended gastrin 17 which is also a stomach and pancreatic cancer growth factor.
Innovators Monograph
You find simplified version here G17DT